Stronghold Plus
selamectin / sarolaner
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Stronghold Plus. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Stronghold Plus.
For practical information about using Stronghold Plus, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Stronghold Plus
|
Agency product number |
EMEA/V/C/004194
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Species |
Cats
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QP54AA55
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zoetis Belgium SA
|
Revision |
4
|
Date of issue of marketing authorisation valid throughout the European Union |
08/02/2017
|
Contact address |
Rue Laid Burniat 1 |
Product information
07/12/2021 Stronghold Plus - EMEA/V/C/004194 - R/0008
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Antiparasitic products, insecticides and repellents
-
Macrocyclic lactones
-
combinations
Therapeutic indication
For cats with, or at risk from, mixed parasitic infestations by ticks and fleas, lice, mites, gastrointestinal nematodes or heartworm.
The veterinary medicinal product is exclusively indicated when use against ticks and one or more of the other target parasites is indicated at the same time.